ReviewFrontiers in medicine2022
Endothelial Dysfunction in Psoriasis: An Updated Review.
Review in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Microvascular Reactivity and Systemic Vascular Resistance Reflect Inflammatory Burden in Psoriasis.Biomedicines · 2026Article
- Integrated Assessment of Inflammatory and Lipid-Metabolic Biomarkers in Psoriasis: Implications for Metabolic Syndrome.Life (Basel, Switzerland) · 2026Article
- Erythrodermic psoriasis complicated by immune complex-mediated crescentic glomerulonephritis and atypical hemolytic uremic syndrome: a case report.BMC nephrology · 2026Article
- Hypoxia and oxidative stress related to inflammation and vascular aspects of the pathogenesis of psoriasis.Skin health and disease · 2026Review
- Comparison of All-Cause Mortality in Generalized Pustular Psoriasis and Plaque Psoriasis: A Systematic Review and Meta-Analysis.Dermatology and therapy · 2026Article
- Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study.Dermatology and therapy · 2025Article
- Article
- Review
- Cardiometabolic Comorbidities of Lichen Planus-A Cross-Sectional Comparative Study.Diagnostics (Basel, Switzerland) · 2025Article
- Review
- S1PR1-biased activation drives the resolution of endothelial dysfunction-associated inflammatory diseases by maintaining endothelial integrity.Nature communications · 2025Article
- Association Between Systemic Inflammation, Metabolic Syndrome and Quality of Life in Psoriasis Patients.Life (Basel, Switzerland) · 2025Article
- Editorial: Exploring endothelial injury syndromes: mechanisms, markers, and therapeutic potential.Frontiers in medicine · 2025Article
- Stromal cells and epigenetics: emerging key players of chronic inflammatory skin diseases.BMB reports · 2024Review
- Epicardial Adipose Tissue and Psoriasis: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2024Review
- Calcipotriol/Betamethasone Dipropionate for the Treatment of Psoriasis: Mechanism of Action and Evidence of Efficacy and Safety versus Topical Corticosteroids.Journal of clinical medicine · 2024Review
- Novel biomarkers and psoriasis associated cardiovascular risk.Archives of dermatological research · 2024Article
- The Use of Microbial Modifying Therapies to Prevent Psoriasis Exacerbation and Associated Cardiovascular Comorbidity.Inflammation · 2024Review
- HPLC- and NMR-Based Chemical Profiling, Wound-Healing Potential, Anti-Inflammatory and Antibacterial Activities ofPlants (Basel, Switzerland) · 2023Article
- Inhibition of vascular endothelial growth factor-A downregulates angiogenesis in psoriasis: A pilot study.Skin health and disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although psoriasis is predominantly a chronic inflammatory skin disorder, epidemiological data provide a solid link between psoriasis, especially in its more severe forms, and increased risk for cardiovascular morbidity and mortality. Apart from the increased prevalence of traditional cardiovascular risk factors, chronic inflammation appears to act synergistically with the underlying process of endothelial dysfunction toward the development of accelerated atherosclerosis, subclinical vascular injury and subsequently, clinically evident cardiovascular manifestations. Endothelial dysfunction is regarded as an early precursor of atherosclerosis with a predictive value for the development of future cardiovascular events. A thorough understanding of the mechanisms of endothelial dysfunction in psoriasis might pave the path for the development of more accurate cardiovascular risk prediction tools and possible therapeutic targets aiming to alleviate the increased cardiovascular burden associated with the disease. The present review summarizes the available evidence about the role of chronic inflammation and other important pathophysiological mechanisms involved in the development of endothelial dysfunction in psoriasis. An overview of studies implementing the most widely applied circulating and vascular biomarkers of endothelial dysfunction in psoriasis patients will be provided, and the impact of systemic psoriasis treatments on endothelial dysfunction and patients' cardiovascular risk will be discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.